虛擬臨床試驗市場－全球產業規模、佔有率、趨勢、機會、預測：依研究設計、適應症、階段、地區和競爭格局分類，2021-2031年

全球虛擬臨床試驗市場預計將從 2025 年的 87.9 億美元大幅成長至 2031 年的 164.6 億美元，複合年成長率達 11.02%。

該市場的一個關鍵特徵是高度依賴分散式研究解決方案，利用遠端醫療、遠端患者監護和數位資料收集工具等技術，最大限度地減少臨床試驗對實體設施的依賴。主要促進因素包括：需要透過提高便利性來提升患者留存率，以及確保能夠接觸到更廣泛、更多樣化的受試者群體這一策略目標。例如，預計到2025年，亞洲地區分散式試驗模式的參與率將達到20.9%，超過傳統試驗的14.2%。這表明分佈式試驗模式在克服地域障礙和建構具有代表性的臨床證據方面具有顯著優勢。

儘管取得了成長，但市場進一步擴張的主要障礙在於，在各種不受控制的遠端環境中維護資料完整性和確保合規性本身就非常複雜。整合各種個人設備和數位平台既帶來了網路安全漏洞，也帶來了標準化方面的挑戰，這給尋求滿足全球衛生監管機構嚴格檢驗標準的申辦者構成了重大障礙。隨著數據在傳統臨床環境之外不斷成長，如何在不給醫療機構工作人員造成過重負擔的情況下確保品質保證的一致性，仍然是一項持續的營運挑戰。

市場促進因素

遠端保健和遠端患者監護解決方案的普及是全球虛擬臨床試驗市場的主要驅動力。這源自於申辦方日益整合數位化工具以實現研究實施的現代化。這項演變的特點是從孤立的先導計畫轉向公司範圍內部署平台，從而促進遠端資料收集和病人參與。 Medable 在 2025 年 1 月的新聞稿中指出，由於在產品組合層面實施了電子臨床結果評估 (eCOA)，其 2024 年的收入成長了 80%，這凸顯了行業向可擴展、分散式技術發展的明顯趨勢。此外，使用穿戴式裝置的研究也支持了這些技術的營運成功。根據臨床研究專業人員協會 (ACRP) 2024 年 10 月發表的一篇報導，這些研究表明患者依從率高達 70% 至 80%，證實了遠距方法在持續生成數據方面的可行性。

同時，隨著人們越來越重視提高臨床試驗的多元性和包容性，虛擬試驗方法正被積極推廣，使以往代表性不足的人群也能參與其中。傳統的基於試驗點的模式往往由於地域限制而難以招募到多元化人群，而分散式方法則有助於更廣泛社區的參與。塔夫茨大學藥物研發研究中心於2025年1月發表的一項研究表明，美洲原住民和阿拉斯加原住民參與分散式臨床試驗的比例達到了1.9%，幾乎是傳統試驗中通常0.5%的四倍。這些數據表明，虛擬試驗能夠彌合醫療保健方面的差距，並使藥物研發適應患者群體多樣化的人口統計特徵。

市場挑戰

在不受控制的遠端環境中確保資料完整性和合規性是一項重大挑戰，嚴重阻礙了全球虛擬臨床試驗市場的發展。對眾多個人設備和各種數位平台的依賴導致數據品質有顯著差異，從而使衛生監管機構要求的檢驗流程變得複雜。這種缺乏標準化迫使申辦方實施成本高且冗餘的檢驗層，削弱了分散式模型通常帶來的效率提升，並常常導致企業為了規避監管風險而推遲大規模部署。

此外，數位化足跡的擴張必然會增加網路安全威脅，並引發人們對高度敏感的病患資訊安全的嚴重擔憂。在安全措施不足的遠端環境中，資料外洩的風險會削弱信任，並迫使人們實施資源密集的安全協議，從而進一步加重臨床實驗機構的營運負擔。根據皮斯托亞聯盟 (Pistoia Alliance) 2024 年的報告，41% 的生命科學專業人士認為資料隱私和安全問題是採用新型數位研究技術的主要障礙。這表明，安全漏洞直接導致該行業持謹慎態度，由於申辦方優先考慮資料安全而非廣泛採用分散式調查方法，因此有效地減緩了市場擴張。

市場趨勢

人工智慧和機器學習的融合正在從根本上改變臨床試驗市場，有效管理處理來自遠端感測器和分散式資料來源的大量資料集所帶來的複雜操作。隨著虛擬臨床試驗超越初始試點階段，申辦方正大力投資演算法能力，以實現試驗組模擬的自動化、病患依從性的精準預測以及即時安全訊號的檢測。這項技術進步正推動產業從被動監測轉向主動預測的試驗管理，確保從數位資料中提煉出可操作的臨床洞見。先進技術基礎設施的投入也體現在大規模投入上，例如賽默飛世爾科技旗下臨床研究營業單位PPD在2023年投資13億美元用於研發，以開發包括先進疾病模擬和人工智慧整合在內的新技術。

同時，直接向患者提供藥物配送和物流系統的建立，正在建立一個強大的實體基礎設施，與分散式試驗數位化進程相輔相成。這一趨勢反映了臨床供應鏈的「亞馬遜化」進程，即臨床實驗藥物（IMP）精準且通常低溫運輸送達患者家中，正從特殊情況轉變為標準操作要求。為了推動這種模式，合約研發受託製造廠商（CDMO）正在擴展其能力，以管理居家給藥所需的複雜、對溫度敏感的藥物-醫療設備組合療法。例如，PCI Pharma Services於2024年9月在歐盟和美國投資超過3.65億美元用於設施擴建。此舉旨在支持臨床和商業規模的藥物-醫療設備組合的組裝和包裝，從而直接滿足日益成長的以患者為中心的供應機制的需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球虛擬臨床試驗市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 研究設計（介入研究、觀察性研究、擴大取得途徑）
  • 按適應症（腫瘤科、心血管疾病科、其他科）
  • 測試階段（第一階段、第二階段、第三階段、第四階段）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美虛擬臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲虛擬臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區虛擬臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲虛擬臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲虛擬臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球虛擬臨床試驗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Medable, Inc.
• ICON, plc
• Parexel International Corporation
• Medidata Solutions Inc
• Oracle Corp
• Signant Health Holding Corp.
• Leo Laboratories Ltd
• IQVIA Inc
• PRA Health Sciences Inc
• Clinical Ink Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Virtual Clinical Trials Market is projected to expand significantly, growing from USD 8.79 Billion in 2025 to USD 16.46 Billion by 2031, demonstrating an 11.02% CAGR. This market is characterized by its reliance on decentralized research solutions, employing technologies such as telemedicine, remote patient monitoring, and digital data collection tools to conduct clinical studies with minimal physical site dependency. Key drivers include the crucial need for enhanced patient retention through increased convenience and the strategic goal of accessing broader, more diverse participant pools. For instance, in 2025, decentralized trial models showed a higher Asian participant representation of 20.9% compared to 14.2% in traditional studies, highlighting their effectiveness in overcoming geographical barriers and fostering representative clinical evidence.

Despite this growth, a significant obstacle to widespread market expansion is the inherent complexity of maintaining data integrity and ensuring regulatory compliance across varied, uncontrolled remote environments. Integrating diverse personal devices and digital platforms introduces both cybersecurity vulnerabilities and standardization challenges, creating substantial hurdles for sponsors aiming to meet stringent validation standards from global health authorities. As data proliferates outside traditional clinical settings, ensuring consistent quality assurance without overstraining site staff remains a persistent operational challenge.

Market Driver

The widespread adoption of telehealth and remote patient monitoring solutions is a primary accelerator for the Global Virtual Clinical Trials Market, as sponsors increasingly integrate digital tools to modernize study execution. This evolution is marked by a shift from isolated pilot projects to enterprise-wide deployment of platforms facilitating remote data capture and patient engagement. Medable's January 2025 press release, highlighting 80% revenue growth in 2024 from portfolio-level electronic Clinical Outcomes Assessment (eCOA) adoption, confirms a definitive industry movement towards scalable decentralized technologies. Furthermore, the operational success of these technologies is evidenced by wearable device studies, which, according to an October 2024 article by the Association of Clinical Research Professionals, demonstrated high patient adherence rates of 70% to 80%, affirming the viability of remote methods for consistent data generation.

Concurrently, an intensified focus on enhancing diversity and inclusion in clinical studies is actively propelling the adoption of virtual trial methods, enabling access to previously underrepresented demographics. Traditional site-based models often struggle with recruiting diverse populations due to geographical limitations, whereas decentralized approaches facilitate participation from a wider array of community settings. Findings from the Tufts Center for the Study of Drug Development in January 2025 indicated that enrollment of American Indian or Alaska Native participants in decentralized clinical trials reached 1.9%, nearly quadrupling the 0.5% rate typically seen in traditional studies. This data underscores virtual trials' capacity to bridge health equity gaps and align drug development with the diverse demographic realities of patient populations.

Market Challenge

Ensuring data integrity and regulatory compliance across uncontrolled remote environments presents a formidable challenge, significantly impeding the growth of the Global Virtual Clinical Trials Market. The reliance on a multitude of personal devices and diverse digital platforms introduces considerable variability in data quality, thereby complicating the validation processes mandated by health authorities. This absence of standardization compels sponsors to implement costly, redundant verification layers, which diminishes the efficiency gains typically associated with decentralized models and often causes companies to defer large-scale adoption to mitigate regulatory risks.

Moreover, the expanded digital footprint inherently magnifies cybersecurity threats, fostering significant hesitation regarding the security of sensitive patient information. The potential for data breaches in non-secure remote settings erodes trust and necessitates the implementation of resource-intensive security protocols that further burden site operations. A 2024 report by the Pistoia Alliance revealed that 41% of life science professionals identified data privacy and security concerns as a principal barrier to adopting new digital research technologies, illustrating how security vulnerabilities directly contribute to the industry's cautious approach and effectively slow market expansion as sponsors prioritize data safety over broader decentralized methodology deployment.

Market Trends

The integration of AI and machine learning for trial optimization is fundamentally reshaping the market by effectively managing the operational complexities involved in processing vast datasets from remote sensors and decentralized sources. As virtual trials progress beyond initial pilot phases, sponsors are making substantial investments in algorithmic capabilities to simulate study arms, accurately predict patient adherence, and automate real-time safety signal detection. This technological evolution transitions the industry from merely reactive monitoring to proactive, predictive study management, ensuring that the high volume of incoming digital data yields actionable clinical insights. This commitment to advanced technological infrastructure is evident in significant capital allocations, such as Thermo Fisher Scientific's clinical research business PPD investing $1.3 billion in research and development in 2023 for new technologies, including advanced disease simulation and AI integration.

Concurrently, the establishment of direct-to-patient drug supply and logistics is developing a robust physical infrastructure that complements the digital advancements in decentralized studies. This trend reflects the "Amazon-ification" of clinical supply chains, where the precise, often cold-chain, delivery of investigational medicinal products (IMPs) directly to patients' homes is transitioning from an exception to a standard operational requirement. To facilitate this model, contract development and manufacturing organizations are expanding their capacities to manage complex, temperature-sensitive, and drug-device combination therapies necessary for home administration. PCI Pharma Services, for instance, committed over $365 million in September 2024 to expand its EU and US facilities, specifically to support the clinical and commercial-scale assembly and packaging of drug-device combination products, directly addressing the increasing demand for patient-centric delivery mechanisms.

Key Market Players

• Medable, Inc.
• ICON, plc
• Parexel International Corporation
• Medidata Solutions Inc
• Oracle Corp
• Signant Health Holding Corp.
• Leo Laboratories Ltd
• IQVIA Inc
• PRA Health Sciences Inc
• Clinical Ink Inc

Report Scope

In this report, the Global Virtual Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Virtual Clinical Trials Market, By Study Design

• Interventional
• Observational
• Expanded Access

Virtual Clinical Trials Market, By Indication

• Oncology
• Cardiovascular Disease
• Others

Virtual Clinical Trials Market, By Phase

• Phase 1
• Phase 2
• Phase 3
• Phase 4

Virtual Clinical Trials Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Virtual Clinical Trials Market.

Available Customizations:

Global Virtual Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Virtual Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Study Design (Interventional, Observational, Expanded Access)
  • 5.2.2. By Indication (Oncology, Cardiovascular Disease, Others)
  • 5.2.3. By Phase (Phase 1, Phase 2, Phase 3, Phase 4)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Virtual Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Study Design
  • 6.2.2. By Indication
  • 6.2.3. By Phase
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Virtual Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Study Design
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Phase
  • 6.3.2. Canada Virtual Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Study Design
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Phase
  • 6.3.3. Mexico Virtual Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Study Design
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Phase

7. Europe Virtual Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Study Design
  • 7.2.2. By Indication
  • 7.2.3. By Phase
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Virtual Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Study Design
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Phase
  • 7.3.2. France Virtual Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Study Design
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Phase
  • 7.3.3. United Kingdom Virtual Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Study Design
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Phase
  • 7.3.4. Italy Virtual Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Study Design
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Phase
  • 7.3.5. Spain Virtual Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Study Design
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Phase

8. Asia Pacific Virtual Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Study Design
  • 8.2.2. By Indication
  • 8.2.3. By Phase
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Virtual Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Study Design
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Phase
  • 8.3.2. India Virtual Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Study Design
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Phase
  • 8.3.3. Japan Virtual Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Study Design
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Phase
  • 8.3.4. South Korea Virtual Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Study Design
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Phase
  • 8.3.5. Australia Virtual Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Study Design
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Phase

9. Middle East & Africa Virtual Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Study Design
  • 9.2.2. By Indication
  • 9.2.3. By Phase
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Virtual Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Study Design
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Phase
  • 9.3.2. UAE Virtual Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Study Design
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Phase
  • 9.3.3. South Africa Virtual Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Study Design
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Phase

10. South America Virtual Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Study Design
  • 10.2.2. By Indication
  • 10.2.3. By Phase
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Virtual Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Study Design
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Phase
  • 10.3.2. Colombia Virtual Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Study Design
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Phase
  • 10.3.3. Argentina Virtual Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Study Design
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Phase

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Virtual Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Medable, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ICON, plc
• 15.3. Parexel International Corporation
• 15.4. Medidata Solutions Inc
• 15.5. Oracle Corp
• 15.6. Signant Health Holding Corp.
• 15.7. Leo Laboratories Ltd
• 15.8. IQVIA Inc
• 15.9. PRA Health Sciences Inc
• 15.10. Clinical Ink Inc

16. Strategic Recommendations

17. About Us & Disclaimer